UK markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.67+0.36 (+3.49%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.31
Open10.35
Bid10.53 x 1300
Ask10.56 x 1000
Day's range10.35 - 10.67
52-week range10.15 - 15.44
Volume67,489
Avg. volume83,455
Market cap404.394M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.80
Earnings date06 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est37.33
  • Globe Newswire

    Result of General Meetings

    DUBLIN, Ireland, and Boston MA, July 28, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at both of today’s General Meetings were duly passed. Accordingly, at the General Meeting held in relation to the Company’s proposed acquisition of Chiasma, Inc., Amryt Shareholders approved the resolutions

  • Globe Newswire

    Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

    Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6 DUBLIN, Ireland, and Boston MA, July 12, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2021 will be released on Friday, August 6, 2021 at 0700 EDT/1200 BST. Amryt will host a conference call and webcast for a

  • Globe Newswire

    Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings

    Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings DUBLIN, Ireland, and Boston MA, 28 June 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases (the “Company” or “Amryt”), is pleased to announce that: further to the Company's announcement on 5 May 2021 in relation t